All In Biotech

Drug Trial Radar · NCT07157007

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Sep 16, 2025

Primary completion

Feb 16, 2026

Study completion Feb 16, 2026

Sponsor

Lead sponsor
Traws Pharma, Inc.Industry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Conditions

  • COVID - 19

Interventions

  • Ratutrelvir (83-0060) non-randomisedDrug

    83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)

  • PaxlovidDrug

    Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)

  • Ratutrelvir (83-0060)Drug

    83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety based on adverse events incidenceTime frame: 28 days
  2. Safety based on adverse events severityTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Institute of Virology

    Tashkent, Tashkent, Uzbekistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.